chadox1-magea3-nyeso
Vaccineexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2021 (NCT04908111)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Melanoma-associated antigen 3Immunity, active
MAGEA3 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04908111 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2021 | Barinthus Biopharmaceuticals, Cancer Research UK |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Barinthus Biopharmaceuticals | For profit | 1 | 0 | 1 | 2021 |
| Cancer Research UK | Academic/Hospital | 1 | 1 | 1 | 2021 |
2 organizations
Page 1 / 1